Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18 |
| October 26, 2020 | October 2020 Bond Updates |
|
EMERYVILLE, Calif., Oct. 26, 2020 /PRNewswire/ -- Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug... |
| View more at: https://www.prnewswire.com:443/news-releases/santen-announces-us-fda-filing-acceptance-of-new-drug-application-nda-for-cyclosporine-topical-ophthalmic-emulsion-0-1-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18--301159476.ht |
| Related News |
|